Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder

This study has been completed.
Information provided by:
National Institute of Mental Health (NIMH) Identifier:
First received: September 13, 2002
Last updated: February 19, 2009
Last verified: February 2009

This study will evaluate the effectiveness of two cognitive behavioral therapies (CBTs) in treating obsessive compulsive disorder (OCD) in patients who are taking medication but still have residual symptoms.

Condition Intervention
Obsessive-Compulsive Disorder
Behavioral: Exposure and Ritual Prevention (Cognitive Behavioral Therapy)
Behavioral: Stress Management Therapy (Cognitive Behavior Therapy)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: CBT Augmentation for SRI Pharmacotherapy in OCD

Resource links provided by NLM:

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:
  • Obsessive-compulsive symptoms measured at Month 2

Secondary Outcome Measures:
  • General functioning measured at Month 2

Estimated Enrollment: 136
Study Start Date: August 2000
Study Completion Date: January 2007
Detailed Description:

Participants remain on their current OCD medication and are randomly assigned to receive one of two CBTs: exposure and ritual prevention or stress management therapy. Exposure and ritual prevention involves imaginal and in-vivo exposure and requires that participants refrain from ritualizing. Stress management involves relaxation, assertiveness training, and structured problem-solving. Therapy occurs twice per week for 2 months. Participants are assessed verbally by an independent evaluator and are asked to complete self-rating forms. Patients who respond are followed for up to 1 additional year. Participants continue to take the same medication and the same monthly therapy for the first 6 months of follow-up. During the second 6 months of follow-up, participants discontinue therapy but continue taking the same medication.

For information on a related study, please follow this link:


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Obsessive-Compulsive Disorder (OCD) diagnosis
  • Currently taking a serotonin reuptake inhibitor (SRI, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for OCD

Exclusion Criteria:

  • Medical or psychiatric conditions that would make participation in the study hazardous
  • Intensive cognitive-behavioral therapy while on an adequate dose and duration of an SRI for OCD
  Contacts and Locations
Please refer to this study by its identifier: NCT00045903

United States, New York
New York State Psychiactic Institute, Anxiety Disorders Clinic
New York, New York, United States, 10032
United States, Pennsylvania
University of Pennsylvania Center for the Treatment and Study of Anxiety
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Principal Investigator: Michael Liebowitz, MD New York State Psychiatric Institute
Principal Investigator: Edna Foa, MD University of Pennsylvania
  More Information

Additional Information:
No publications provided by National Institute of Mental Health (NIMH)

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00045903     History of Changes
Other Study ID Numbers: R01 MH045436-01, DSIR AT-CT
Study First Received: September 13, 2002
Last Updated: February 19, 2009
Health Authority: United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):
Cognitive Behavioral Therapy

Additional relevant MeSH terms:
Obsessive-Compulsive Disorder
Compulsive Personality Disorder
Anxiety Disorders
Mental Disorders
Personality Disorders processed this record on April 17, 2014